Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Oncol Lett
2016 May 01;115:3515-3521. doi: 10.3892/ol.2016.4396.
Show Gene links
Show Anatomy links
TPX2 in human clear cell renal carcinoma: Expression, function and prognostic significance.
Chen QI, Cao B, Nan N, Wang YU, Zhai XU, Li Y, Chong T.
???displayArticle.abstract???
Targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein. TPX2 is considered to be an important gene in tumorigenesis; however, the particular function of TPX2 in the development of human renal cell carcinoma (RCC) is unknown. In the present study, the expression, function and prognostic significance of TPX2 in human RCC was analyzed. A total of 286 tissue samples from patients with RCC who had undergone nephrectomies were utilized. Subsequently, the expression of TPX2 protein was investigated using immunohistochemistry and western blotting, and TPX2 mRNA expression was examined using reverse transcription-quantitative polymerase chain reaction. To establish the effect of TPX2 on the proliferation and invasion of the RCC cells, TPX2 expression was increased by stable transfection with a TPX2 vector and TPX2 expression was decreased using small interfering RNA. Proliferation of the RCC cells was analyzed using a WST-1 assay and an animal xenograft model with BALB/c nude mice, whilst invasion of the RCC cells was examined using a Matrigel-coated invasion chamber. It was demonstrated that TPX2 expression was significantly higher in the RCC tissues compared with normal kidney tissues (P<0.05). Furthermore, TPX2 expression was associated with tumor size, histological grade and tumor stage (P<0.05), and was observed to markedly increase the proliferation and invasion of the RCC cells. It may be concluded that the expression of TPX2 is significantly upregulated in RCCtissue, subsequently increasing the proliferative and invasive ability of RCC cells. Therefore, the protein may serve as a therapeutic target and independent prognostic factor in the treatment of human RCC.
Anderson,
Met receptor signaling: a key effector in esophageal adenocarcinoma.
2006, Pubmed
Anderson,
Met receptor signaling: a key effector in esophageal adenocarcinoma.
2006,
Pubmed Arai,
Genetic and epigenetic alterations during renal carcinogenesis.
2010,
Pubmed Cáceres-Gorriti,
RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer.
2014,
Pubmed Colak,
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women.
2013,
Pubmed Crane,
Aurora A, meiosis and mitosis.
2004,
Pubmed
,
Xenbase Dasanu,
mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option.
2009,
Pubmed Deng,
Histologic variants of renal cell carcinoma: does tumor type influence outcome?
2012,
Pubmed Elmore,
Reassessment of the 1997 TNM classification system for renal cell carcinoma.
2003,
Pubmed El-Serag,
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.
2003,
Pubmed Engelman,
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.
2006,
Pubmed Gao,
Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9.
2013,
Pubmed Gruss,
Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells.
2002,
Pubmed
,
Xenbase Gupta,
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
2008,
Pubmed Hartmann,
Chemotherapy for renal cell carcinoma.
1999,
Pubmed Hong,
Application of simplified Fuhrman grading system in clear-cell renal cell carcinoma.
2011,
Pubmed Hudes,
mTOR as a target for therapy of renal cancer.
2007,
Pubmed Kan,
The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim.
2009,
Pubmed Kufer,
Human TPX2 is required for targeting Aurora-A kinase to the spindle.
2002,
Pubmed
,
Xenbase Leng,
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
2003,
Pubmed Lin,
[TPX2 expression and its significance in squamous cell carcinoma of lung].
2006,
Pubmed Lin,
Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy.
2014,
Pubmed Liu,
Upregulation of the TPX2 gene is associated with enhanced tumor malignance of esophageal squamous cell carcinoma.
2013,
Pubmed Manning,
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling.
2003,
Pubmed Matsubara,
First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
2013,
Pubmed Ozlü,
An essential function of the C. elegans ortholog of TPX2 is to localize activated aurora A kinase to mitotic spindles.
2005,
Pubmed
,
Xenbase Pascreau,
Phosphorylation of p53 is regulated by TPX2-Aurora A in xenopus oocytes.
2009,
Pubmed
,
Xenbase Robb,
Activation of the mTOR signaling pathway in renal clear cell carcinoma.
2007,
Pubmed Scharer,
Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.
2008,
Pubmed Shigeishi,
Expression of TPX2 in salivary gland carcinomas.
2009,
Pubmed Shigeishi,
Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas.
2009,
Pubmed Stewart,
Anaphase-promoting complex/cyclosome controls the stability of TPX2 during mitotic exit.
2005,
Pubmed Tonon,
High-resolution genomic profiles of human lung cancer.
2005,
Pubmed Trieselmann,
Ran modulates spindle assembly by regulating a subset of TPX2 and Kid activities including Aurora A activation.
2003,
Pubmed
,
Xenbase Waalkes,
Present state of target therapy for disseminated renal cell carcinoma.
2010,
Pubmed Wang,
Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-κB pathways induced by paracrine cytokines.
2013,
Pubmed Wei,
TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer.
2013,
Pubmed Yan,
Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma.
2013,
Pubmed Yu,
The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines.
1998,
Pubmed
